Widely used:Recently Viewed
Clear AllValue Research Rating
Quality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
₹4,986 Cr
Revenue (TTM)
₹1,860 Cr
Net Profit (TTM)
₹91 Cr
ROE
6 %
ROCE
7.8 %
P/E Ratio
54.9
P/B Ratio
4
Industry P/E
39.67
EV/EBITDA
17.2
Div. Yield
0.3 %
Debt to Equity
0.3
Book Value
₹102.4
EPS
₹7.4
Face value
2
Shares outstanding
123,300,750
CFO
₹2,085.38 Cr
EBITDA
₹2,562.27 Cr
Net Profit
₹855.68 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Hikal
| 3.6 | -1.5 | 13.2 | 34.1 | 1.9 | 28.1 | 15.9 |
|
BSE Healthcare
| -5.9 | 0.5 | 7.3 | 18.6 | 22.8 | 22.3 | 9.5 |
|
BSE Small Cap
| -6.0 | 4.8 | 12.4 | 7.4 | 25.0 | 37.4 | 16.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Hikal
| 30.1 | -25.9 | -22.1 | 215.6 | 41.4 | -26.9 | -1.1 |
|
BSE Small Cap
| 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 | -23.4 |
|
BSE Healthcare
| 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 | -5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Hikal
|
404.7 | 4,986.3 | 1,859.8 | 90.8 | 10.4 | 7.4 | 54.9 | 4.0 |
| 866.4 | 7,850.8 | 2,115.1 | 272.4 | 17.8 | 14.2 | 28.8 | 3.9 | |
| 1,168.8 | 9,569.3 | 1,006.9 | 160.4 | 20.4 | 12.6 | 60.3 | 7.3 | |
| 890.5 | 5,087.9 | 1,243.7 | 128.3 | 13.0 | 13.8 | 39.7 | 5.3 | |
| 185.7 | 897.4 | 629.6 | 38.6 | 8.6 | 7.6 | 23.3 | 1.7 | |
| 973.2 | 2,402.8 | 356.3 | 100.9 | 25.0 | 13.3 | 23.8 | 3.1 | |
| 163.3 | 5,302.7 | 71.8 | -342.5 | -467.5 | -- | -- | -24.5 | |
| 140.4 | 1,292.7 | 405.5 | 23.9 | 9.6 | 7.3 | 43.3 | 3.5 | |
| 1,286.1 | 1,817.0 | 801.5 | 81.7 | 3.3 | 6.7 | 22.3 | 1.7 | |
| 287.5 | 944.3 | 597.8 | 30.5 | 10.2 | 62.3 | 30.9 | 15.9 |
No Review & Analysis are available.
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in... India. The company operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. It also collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, the company offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. It also exports its products. The company operates in the United States, Canada, Europe Union, Japan, Latin America, and internationally. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India. Read more
Incorporated
1988
Chairman
Jai Hiremath
Managing Director
Sameer Hiremath
Group
Kalyani
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Hikal Ltd stood at ₹ 2,529 Cr as on 31-Mar-25
The share price of Hikal Ltd is ₹404.70 (NSE) and ₹404.40 (BSE) as of 23-May-2025 IST. Hikal Ltd has given a return of 1.93% in the last 3 years.
Hikal Ltd has a market capitalisation of ₹ 4,986 Cr as on 23-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Hikal Ltd is 3.95 times as on 23-May-2025, a 0% premium to its peers’ median range of 3.95 times.
The P/E ratio of Hikal Ltd is 54.92 times as on 23-May-2025, a 38% premium to its peers’ median range of 39.67 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Hikal Ltd and enter the required number of quantities and click on buy to purchase the shares of Hikal Ltd.
Hikal Limited, together with its subsidiaries, manufactures and sells various chemical intermediates, specialty chemicals, and active pharma ingredients to pharmaceutical, animal health, biotech, crop protection, and specialty chemicals companies in India. The company operates through two segments, Pharmaceuticals and Crop Protection. The Pharmaceuticals segment produces active pharmaceutical ingredient (APIs). The Crop Protection segment manufactures pesticides and herbicides, which include diuron tech, temephos tech, thiacloprid tech, clothianidin tech, dichloroaniline, N-bromosuccinimide, prothioconazole technical, trifloxystrobin technical, and BIT. It also collaborates with other companies and offer solutions in contract research, custom synthesis, and custom manufacturing of intermediates and active ingredients. In addition, the company offers human health products, such as anti-convulsant, anti-emetic, anti-histaminic, anti-depressant, anti-psychotic, anti-lipemic, hemorheologic, anti-diabetic, anti-thrombotic, anti-hypertensive, anti-inflammation, and analgesic; animal health products, such as anti-tick, anti-parasitic, analgesic, anabolic steroids, female sex hormone, and NSAID; and specialty biocides and antimicrobial actives, as well as additives for leather, paint coatings, paper, water treatment, personal care, building materials, and textile industries. It also exports its products. The company operates in the United States, Canada, Europe Union, Japan, Latin America, and internationally. Hikal Limited was incorporated in 1988 and is headquartered in Navi Mumbai, India.
The prominent promoters of Hikal Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Kalyani Investment Company Limited |
31.36%
|
|
Shri Badrinath Investment Pvt Ltd |
16.15%
|
|
Shri Rameshwara Investment Pvt Ltd |
7.96%
|
|
Sugandha J Hiremath |
7.84%
|
The chairman of the company is Jai Hiremath, and the managing director is Sameer Hiremath.
There is no promoter pledging in Hikal Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
9,569
|
|
|
7,851
|
|
|
5,303
|
|
|
5,088
|
|
|
2,403
|
|
|
1,817
|
|
|
1,293
|
|
|
944
|
|
|
897
|
| Hikal Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
7.37
|
|
Operating margin(%)
|
10.43
|
|
Net Margin(%)
|
4.87
|
|
Dividend yield(%)
|
0.35
|
Yes, TTM profit after tax of Hikal Ltd was ₹91 Cr.
₹-1.85
(
